Review



ac16 human cardiomyocytes  (Millipore)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Millipore ac16 human cardiomyocytes
    Impact of DYRK1A overexpression on the relative abundance of endogenous TNNT2 transcript variants in iPSC <t>cardiomyocytes.</t> A PCR amplification strategy for the analysis of fetal ( cTnT1 and cTnT2 ) and adult ( cTnT3 and cTnT4 ) TNNT2 transcript variants. F: forward primer, R: reverse primer. B Relative abundance of TNNT2 transcript variants in basal conditions (control) or in cells overexpressing DYRK1A (DYRK1A). C Relative DYRK1A mRNA fold expression in cells transfected with an empty vector (EV, control) or a DYRK1A expression construct (DYRK1A). D Relative abundance of fetal and adult TNNT2 transcript variants in basal conditions and in cardiomyocytes overexpressing DYRK1A . Each point represents the mean from independent transfections, with two determinations performed in triplicates. Horizontal bars show the mean ± SD. *** P < 0.001, * P < 0.05, ns not significant, Student’s t test
    Ac16 Human Cardiomyocytes, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ac16 human cardiomyocytes/product/Millipore
    Average 90 stars, based on 1 article reviews
    ac16 human cardiomyocytes - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "Impact of DYRK1A Expression on TNNT2 Splicing and Daunorubicin Toxicity in Human iPSC-Derived Cardiomyocytes"

    Article Title: Impact of DYRK1A Expression on TNNT2 Splicing and Daunorubicin Toxicity in Human iPSC-Derived Cardiomyocytes

    Journal: Cardiovascular Toxicology

    doi: 10.1007/s12012-022-09746-6

    Impact of DYRK1A overexpression on the relative abundance of endogenous TNNT2 transcript variants in iPSC cardiomyocytes. A PCR amplification strategy for the analysis of fetal ( cTnT1 and cTnT2 ) and adult ( cTnT3 and cTnT4 ) TNNT2 transcript variants. F: forward primer, R: reverse primer. B Relative abundance of TNNT2 transcript variants in basal conditions (control) or in cells overexpressing DYRK1A (DYRK1A). C Relative DYRK1A mRNA fold expression in cells transfected with an empty vector (EV, control) or a DYRK1A expression construct (DYRK1A). D Relative abundance of fetal and adult TNNT2 transcript variants in basal conditions and in cardiomyocytes overexpressing DYRK1A . Each point represents the mean from independent transfections, with two determinations performed in triplicates. Horizontal bars show the mean ± SD. *** P < 0.001, * P < 0.05, ns not significant, Student’s t test
    Figure Legend Snippet: Impact of DYRK1A overexpression on the relative abundance of endogenous TNNT2 transcript variants in iPSC cardiomyocytes. A PCR amplification strategy for the analysis of fetal ( cTnT1 and cTnT2 ) and adult ( cTnT3 and cTnT4 ) TNNT2 transcript variants. F: forward primer, R: reverse primer. B Relative abundance of TNNT2 transcript variants in basal conditions (control) or in cells overexpressing DYRK1A (DYRK1A). C Relative DYRK1A mRNA fold expression in cells transfected with an empty vector (EV, control) or a DYRK1A expression construct (DYRK1A). D Relative abundance of fetal and adult TNNT2 transcript variants in basal conditions and in cardiomyocytes overexpressing DYRK1A . Each point represents the mean from independent transfections, with two determinations performed in triplicates. Horizontal bars show the mean ± SD. *** P < 0.001, * P < 0.05, ns not significant, Student’s t test

    Techniques Used: Over Expression, Amplification, Expressing, Transfection, Plasmid Preparation, Construct

    DYRK1A protein expression in iPSC cardiomyocytes. A Detection of DYRK1A with an anti-DYRK1A antibody (left panel). β-Tubulin was assayed as loading control (right panel). B Representative fluorescence microscopy of a complete field of view (upper panel) and in one individual cell (lower panels) showing the expression and subcellular distribution of DYRK1A-GFP (green). Cells were analyzed 72 h post-transfection with an empty vector (EV) or a DYRK1A-GFP expression construct
    Figure Legend Snippet: DYRK1A protein expression in iPSC cardiomyocytes. A Detection of DYRK1A with an anti-DYRK1A antibody (left panel). β-Tubulin was assayed as loading control (right panel). B Representative fluorescence microscopy of a complete field of view (upper panel) and in one individual cell (lower panels) showing the expression and subcellular distribution of DYRK1A-GFP (green). Cells were analyzed 72 h post-transfection with an empty vector (EV) or a DYRK1A-GFP expression construct

    Techniques Used: Expressing, Fluorescence, Microscopy, Transfection, Plasmid Preparation, Construct

    SRSF6 phosphorylation in iPSC cardiomyocytes overexpressing DYRK1A . A Evaluation of the anti-phosphoepitope SR antibody in total protein extracts from AC16 cardiomyocytes treated with calf intestine alkaline phosphatase (CIAP). B Detection of phospho-SRSF6 and SRSF6 in iPSC cardiomyocytes transfected with empty vector (EV), SRSF6-HA expression construct (SRSF6) or co-transfected with DYRK1A and SRSF6-HA (SRSF6 + DYRK1A). β-Tubulin was assayed as loading control. Lower panel: densitometric analysis. Upper right panel: relative DYRK1A mRNA fold expression. (A.U.: arbitrary units). C Detection of phosphorylated SRSF6 in immunoprecipitated samples from iPSC cardiomyocytes. Right panel: densitometric analysis. Horizontal bars show the mean ± SD from determinations performed in quintuplicate. D Dot-blot analysis of phosphorylated SRSF6 in immunoprecipitated samples. Right panel: densitometric analysis. Horizontal bars show the mean ± SD from determinations performed in quintuplicate. *** P < 0.001, * P < 0.05, Student’s t test
    Figure Legend Snippet: SRSF6 phosphorylation in iPSC cardiomyocytes overexpressing DYRK1A . A Evaluation of the anti-phosphoepitope SR antibody in total protein extracts from AC16 cardiomyocytes treated with calf intestine alkaline phosphatase (CIAP). B Detection of phospho-SRSF6 and SRSF6 in iPSC cardiomyocytes transfected with empty vector (EV), SRSF6-HA expression construct (SRSF6) or co-transfected with DYRK1A and SRSF6-HA (SRSF6 + DYRK1A). β-Tubulin was assayed as loading control. Lower panel: densitometric analysis. Upper right panel: relative DYRK1A mRNA fold expression. (A.U.: arbitrary units). C Detection of phosphorylated SRSF6 in immunoprecipitated samples from iPSC cardiomyocytes. Right panel: densitometric analysis. Horizontal bars show the mean ± SD from determinations performed in quintuplicate. D Dot-blot analysis of phosphorylated SRSF6 in immunoprecipitated samples. Right panel: densitometric analysis. Horizontal bars show the mean ± SD from determinations performed in quintuplicate. *** P < 0.001, * P < 0.05, Student’s t test

    Techniques Used: Transfection, Plasmid Preparation, Expressing, Construct, Immunoprecipitation, Dot Blot

    Impact of DYRK1A overexpression on the relative abundance of TNNT2 transcript variants in iPSC cardiomyocytes transfected with SRSF6 . A Relative abundance of TNNT2 transcript variants in cells transfected with an SRSF6-HA (SRSF6) or co-transfected with DYRK1A-GFP and SRSF6 expression constructs (SRSF6-DYRK1A). B Relative DYRK1A mRNA fold expression in transfected cells. C Relative abundance of cTnT1 and cTnT2 (left), cTnT3 (center), and cTnT4 (right) transcript variants. Horizontal bars show the mean ± SD from three independent transfections per condition, with 2–3 determinations performed in triplicate. *** P < 0.001, * P < 0.05, ns not significant, Student’s t test. D Impact of SRSF6 overexpression on the relative abundance of cTnT1 and cTnT2 in cells with basal levels of DYRK1A (left), or overexpressing DYRK1A (right). ** P < 0.01, * P < 0.05, ns not significant. One-way ANOVA (Tukey’s test)
    Figure Legend Snippet: Impact of DYRK1A overexpression on the relative abundance of TNNT2 transcript variants in iPSC cardiomyocytes transfected with SRSF6 . A Relative abundance of TNNT2 transcript variants in cells transfected with an SRSF6-HA (SRSF6) or co-transfected with DYRK1A-GFP and SRSF6 expression constructs (SRSF6-DYRK1A). B Relative DYRK1A mRNA fold expression in transfected cells. C Relative abundance of cTnT1 and cTnT2 (left), cTnT3 (center), and cTnT4 (right) transcript variants. Horizontal bars show the mean ± SD from three independent transfections per condition, with 2–3 determinations performed in triplicate. *** P < 0.001, * P < 0.05, ns not significant, Student’s t test. D Impact of SRSF6 overexpression on the relative abundance of cTnT1 and cTnT2 in cells with basal levels of DYRK1A (left), or overexpressing DYRK1A (right). ** P < 0.01, * P < 0.05, ns not significant. One-way ANOVA (Tukey’s test)

    Techniques Used: Over Expression, Transfection, Expressing, Construct

    Impact of DYRK1A expression and drug treatments on the viability of iPSC cardiomyocytes. A Cellular viability after incubations with daunorubicin (DAU) and epigallocatechin gallate (EGCG). B Viability in controls and DYRK1A- overexpressing cells. Mean ± SD from two determinations performed in triplicates. *** P < 0.001, ** P < 0.01, ns not significant, One-way ANOVA (Tukey’s test) and Student’s t test
    Figure Legend Snippet: Impact of DYRK1A expression and drug treatments on the viability of iPSC cardiomyocytes. A Cellular viability after incubations with daunorubicin (DAU) and epigallocatechin gallate (EGCG). B Viability in controls and DYRK1A- overexpressing cells. Mean ± SD from two determinations performed in triplicates. *** P < 0.001, ** P < 0.01, ns not significant, One-way ANOVA (Tukey’s test) and Student’s t test

    Techniques Used: Expressing

    Analysis of iPSC cardiomyocytes contractility. A Beating rate in cardiomyocytes overexpressing DYRK1A in control conditions (left) and after exposure to daunorubicin (DAU) (middle). Right: relative DYRK1A fold expression in transfected cells. Each point represents individual measurements in a region of interest (ROI) ( n = 45–55 ROIs per condition). Each bar represents the mean ± SD of three measurements performed in triplicates for each condition. * P < 0.05, ns not significant, Student’s t test. B Representative fluorograms showing beating patterns from controls and treated cells. C Representative live-confocal microscopy images of iPSC cardiomyocytes showing changes in Fluo-4 AM intensity (green) over time. Scale bar: 50 µm
    Figure Legend Snippet: Analysis of iPSC cardiomyocytes contractility. A Beating rate in cardiomyocytes overexpressing DYRK1A in control conditions (left) and after exposure to daunorubicin (DAU) (middle). Right: relative DYRK1A fold expression in transfected cells. Each point represents individual measurements in a region of interest (ROI) ( n = 45–55 ROIs per condition). Each bar represents the mean ± SD of three measurements performed in triplicates for each condition. * P < 0.05, ns not significant, Student’s t test. B Representative fluorograms showing beating patterns from controls and treated cells. C Representative live-confocal microscopy images of iPSC cardiomyocytes showing changes in Fluo-4 AM intensity (green) over time. Scale bar: 50 µm

    Techniques Used: Expressing, Transfection, Confocal Microscopy



    Similar Products

    Image Search Results